V Square Quantitative Management LLC Trims Stake in Stryker Corporation $SYK

Key Points

• V Square Quantitative Management LLC has reduced its stake in Stryker Corporation by 40.4%, now holding 3,465 shares valued at approximately $1.37 million.
• Insider transactions include Ronda E. Stryker selling 200,000 shares for about $75.29 million, representing a 5.84% decrease in her holdings.
• Stryker Corporation's stock has a market capitalization of $141.01 billion and an average target price of $430.33, with a consensus rating of "Moderate Buy."

V Square Quantitative Management LLC reduced its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 40.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,465 shares of the medical technology company's stock after selling 2,351 shares during the period. V Square Quantitative Management LLC's holdings in Stryker were worth $1,371,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Goodman Advisory Group LLC purchased a new stake in Stryker during the first quarter valued at approximately $32,000. City Holding Co. increased its holdings in Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after buying an additional 74 shares during the last quarter. Ridgewood Investments LLC increased its holdings in Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company's stock valued at $36,000 after buying an additional 30 shares during the last quarter. Ransom Advisory Ltd purchased a new stake in Stryker during the first quarter valued at approximately $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in Stryker during the first quarter valued at approximately $40,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Viju Menon sold 500 shares of the stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.20% of the company's stock.

Stryker Stock Performance

SYK opened at $368.83 on Monday. The stock has a market capitalization of $141.01 billion, a price-to-earnings ratio of 48.85, a PEG ratio of 2.66 and a beta of 0.93. The company has a fifty day moving average of $385.71 and a 200 day moving average of $379.18. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker's quarterly revenue was up 11.1% on a year-over-year basis. During the same period last year, the company posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, sell-side analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is presently 44.50%.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Truist Financial set a $415.00 target price on shares of Stryker and gave the company a "hold" rating in a report on Monday, August 4th. Rothschild Redb raised shares of Stryker to a "hold" rating in a research note on Thursday, September 18th. Wells Fargo & Company increased their price objective on shares of Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Rothschild & Co Redburn initiated coverage on shares of Stryker in a research note on Thursday, September 18th. They issued a "neutral" rating and a $420.00 price objective for the company. Finally, Needham & Company LLC increased their price objective on shares of Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Fourteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Stryker presently has a consensus rating of "Moderate Buy" and an average price target of $430.33.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.